(Alliance News) - Life sciences company MaxCyte Inc on Wednesday reported first half revenue growth but its loss widened as expenses soared.In the six months to June 30, the firm's rose Read More
(Alliance News) - MaxCyte Inc on Wednesday reported double-digit revenue growth in the first half of 2019 and expects to see continued progress throughout the second half of the year.The is Read More
LONDON (Alliance News) - MaxCyte Inc on Wednesday said it has begun dosing for the second cohort of patients in its phase one trial of cancer drug MCY-M11.Shares in MaxCyte were down 5.7% a Read More
LONDON (Alliance News) - MaxCyte Inc on Wednesday said its loss narrowed in 2018 on higher annual fees from its partners as it progresses on MCY-M11 therapeutic candidate development.The a Read More
LONDON (Alliance News) - MaxCyte Inc on Monday announced the launch of its new ExPERT technology platform for use in cellular engineering.MaxCyte also noted that its business had produced Read More
LONDON (Alliance News) - Biotechnology company MaxCyte Inc on Friday said it has expanded its business relationship with Kite by signing a multi-drug clinical and commercial agreement.Under Read More
LONDON (Alliance News) - MaxCyte Inc on Tuesday said it has raised GBP10.0 million from a placing of 5.9 million shares at 170 pence each.The life sciences company placed 5.9 million just Read More
LONDON (Alliance News) - MaxCyte Inc on Tuesday said it plans to raise at least GBP10 million via a placing of shares in order to accelerate its growth strategy.The life sciences company no Read More
LONDON (Alliance News) - MaxCyte Inc on Tuesday guided for a 19% increase in its 2018 revenue with the firm expecting its annual earnings to exceed market views.The life science company in Read More
LONDON (Alliance News) - Life sciences and medicines company MaxCyte Inc on Wednesday said it has dosed the first patient in its phase I trial for MCY-M11.MCY-M11 is a mesothelin targeting Read More
